Search results for " regulations"

Article USP Stresses Pharmacopeial Standards at CPhI China
Topics included global harmonization with industry standards and regulations, compliance monitoring, and accountability. The USP requirements for elemental impurities, FDA’s metrics program, and the g…

Article Optimization of Protein Expression in Escherichia Coli
May 01, 2015 By Siavash Bashiri, David Vikström, Nurzian Ismail BioPharm International Volume 28, Issue 5 Production of proteins for manufacturing therapeutics and pharmaceuticals is a c…

Article Labeling of Biosimilars
EMA is under pressure to exert even tighter standards on biosimilars being marketed in Europe. Feb 01, 2015 By Sean Milmo BioPharm International The European Medicines Agency (EMA) has r…

Article Brazil Emerges as Global Biopharm Collaborator
Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator. The pharmaceutical market in Brazil has been growing steadily and strongly in the past five ye…

Article FDA Seeks Metrics to Define Drug Quality
While producers of food products and fine chemicals have engineered precise controls that yield defect-free products, she finds that pharmaceutical companies focus more on complying with regulations. …

Article Navigating Emerging Markets: Middle East and North Africa
The pharmaceutical industry grows despite conflict in the Middle East. The Middle East and North Africa have been rocked in recent years by upheaval ranging from moderate protest to full…

Article Elucidating Biosimilars Characterization
The global market for biosimilar drugs has been forecasted to be $2.445 billion in 2013 according to a report by the British market-research firm, Visiongain (1). The growth corresponds to a …

Article Report from India
Pharma industry players brace for challenges as India’s new drug-pricing policy kicks in full gear. (Dmitry Rukhlenko/Getty Images) On July 1, India's new…

Article Quality by design for biotechnology products—part 1
Guidance for Industry: Q10 Quality systems approach to pharmaceutical CGMP regulations. Bethesda, MD; 2006. 4. US FDA. Guidance for industry: PAT—A framework for innovative pharmaceutical developm…

Article Quality Considerations for Using AI in Bio/Pharma
The use of artificial intelligence (AI) is seeing a surge in a variety of industries. But does the regulated nature of bio/pharmaceutical development, manufacturing, and commercialization ser…

Previous PageNext Page